This story was originally published on CFO Dive. To receive daily news and insights, subscribe to our free daily CFO Dive newsletter. Dive Brief: The Securities and Exchange Commission said Wednesday that Gibson Dunn attorney James J. Moloney has been named director of the agency’s Division of Corporation Finance, effective next month. Cicely LaMothe, who has served as acting director, will return to her role as a deputy director of the division, the agency said. “Jim is a seasoned professional who und ...

Core Insights - NeOnc Technologies Holdings, Inc. has achieved a significant milestone by executing a Sub-License Agreement with its Abu Dhabi subsidiary, NuroCure, covering the UAE and wider GCC and MENA region for its therapeutics NEO100 and NEO212 [1][2] - The company is progressing towards a strategic partnership with Quazar Investment, which includes a potential $50 million equity investment aimed at expanding operations in the MENA region [2][5] - NeOnc's inclusion in the Russell Microcap Index is strategically timed with the Quazar partnership to attract institutional capital and enhance market liquidity [3] Company Developments - The Sub-License Agreement is the second of five required conditions for closing the transaction with Quazar, indicating progress in the partnership [2][5] - The proposed capital formation round led by Quazar is priced at $25 per share, with 70% of proceeds allocated for acquiring NeOnc common stock and 30% for clinical trials and infrastructure development in the MENA region [5] - NeOnc's NEO100 and NEO212 therapeutics are currently in Phase II clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status, showcasing the company's commitment to advancing life-saving therapies [6] Strategic Goals - The completion of the Sub-License Agreement is viewed as a critical step in unlocking the full potential of the $50 million partnership, aimed at delivering long-term value to shareholders [4] - The company is undergoing a transformation from a clinical-stage biotech to a global brain cancer platform, as noted by industry experts [4] - NeOnc has an extensive patent portfolio licensed from the University of Southern California, which supports its drug development efforts and extends patent protections to 2038 [6]

Industry Trends - Onchain trading, capital formation, and payments are approaching a point where they offer superior products compared to offchain alternatives [1] - The industry anticipates rapid changes once the threshold of onchain solutions surpassing offchain options is crossed [1]